Studies indicate that the potential activation of the NLRP3 inflammasome by SARS-CoV-2 directly leads to elevated levels of pro-inflammatory cytokines IL-1β and IL-18 in severe COVID-19 patients, which are associated with adverse outcomes (44). The gene discussed is IL18; the disease is COVID-19.